AACR 2024 | Clonal hematopoiesis mutations in ovarian carcinomas

Rebecca Porter, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the implications of current research on clonal hematopoiesis mutations in ovarian carcinomas. A recent study on blood cells of patients with ovarian cancer before, during and after treatment demonstrated increased occurrence of clonal hematopoiesis in patients who receive chemotherapies such as platinum chemotherapy or PARP inhibitors. Further research is required to understand the factors associated with increased risk of clonal hematopoiesis. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.